AbCellera, a technology company with a centralized operating system for next-generation antibody discovery, agreed to acquire TetraGenetics, a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins. Financial terms were not disclosed. "AbCellera is committed to investing in teams and technologies that have the potential to create new therapeutic opportunities, drive more value in our partnership business, and bring new therapies to patients. We look forward to welcoming the TetraGenetics team and believe that these new capabilities, once integrated into AbCellera’s technology stack, will empower the discovery of new antibody therapies across a range of therapeutic areas," Carl Hansen, AbCellera CEO.